Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE
01-08-20072. REPORT TYPE
Annual
DATES COVERED
PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 8. PERFORMING ORGANIZATION REPORT NUMBERUniversity of Alabama at Birmingham Birmingham, AL 35294-0111
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTNanotechnology holds many promises for the imaging and treatment of breast cancer. In particular, magnetic nanoparticles can be utilized for tumor imaging via magnetic resonance imaging (MRI) techniques and tumor treatment by heating after exposure to an alternating magnetic field. However, selective targeting of the nanoparticles to the tumor cells needs to be accomplished before the imaging or therapy can be successful. In this respect, adenoviral (Ad) vectors for gene therapy have made great progress in achieving successful tumor targeting after their intravenous administration. We therefore hypothesized that coupling magnetic nanoparticles to targeted Ad vectors would allow the selective localization of these particles to the tumor, thereby making imaging and therapy possible. We herein identified that coupling the nanoparticles to the Ad capsid protein hexon does not perturb vector infectivity or retargeting efficiency in vitro. Furthermore, we have demonstrated the intracellular accumulation of nanoparticles targeted to breast cancer cells using this system. We will continue this project by identifying novel magnetic nanoparticles with optimal magnetic contrast properties for imaging and treatment of breast cancer cells, and will also broaden our project's scope by including Quantum Dots in addition to magnetic nanoparticles for the imaging of tumors. This will further our goal to develop multifunctional systems for targeting, imaging and treatment of cancer.
SUBJECT TERMS
BODY
Coupling nanoparticles to Ad vectors -hexon is the best capsid location.To accomplish the development of mu...